Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with
substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the …

Health-related quality of life (HRQoL), though rarely considered as a primary endpoint in
clinical trials, may be the single outcome reflective of patient priorities when living with a …

Background Current guidelines recommend 20–40 mg· day− 1 of oral prednisolone for
treating pulmonary sarcoidosis. Whether the higher dose (40 mg· day− 1) can improve …

Study objectives To describe the health-related quality of life (HRQL) and mental health of
persons with sarcoidosis, as well as to assess physician-patient agreement about the …

Publisher Correction: Sarcoidosis Johan Grunewald, Jan C. Grutters, Elizabeth
V. Arkema, Lesley Ann Saketkoo, David R. Moller and Joachim M ller …

Rationale: Socioeconomic factors are associated with worse disease severity at
presentation in sarcoidosis, but the relative importance of socioeconomic variables on …

Background: The 6-min walk test has proved useful in assessing impairment and prognosis
in various lung diseases. Methods: A prospective study of 142 sarcoidosis patients seen …

Sarcoidosis is a multisystem, noncaseating granulomatous disorder of unknown cause with
skin as the second most common organ affected, occurring in 25% to 30% of cases reported …

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It
affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is …

Not all patients who have sarcoidosis require treatment. For those who require treatment, the
outcome of sarcoidosis can be considered conceptually in three broad, and at least partially …